

I repeat—all sides will be heard as I have said in the beginning. And I cannot hear them all at once.

I suppose Dr. Apple could have complained. I apologized to him yesterday. I said, "You are the first representative of the pharmacists which I have called, and tomorrow Mr. Stetler will appear. If there is a complaint about the order in which you are called or about how long it has taken, you have the same complaint that Mr. Stetler has expressed all over the United States. But at least I have told Mr. Stetler to have every single company who supports his association to appear before the committee, and we have only had two volunteers."

So I repeat my offer for them to come again. All the viewpoints will be heard. I cannot hear them all at once. I suppose if you were chairman, we would have a different order in which you would call them.

But I think we have had a long list of very distinguished witnesses although you may differ with them.

Let us take a look at them.

On the fourth day of the hearings we started with experts in the field. We had Dr. Walter Modell, director, clinical pharmacology, Cornell University. Do you consider him an expert witness?

Mr. STETLER. I consider him to be a well-qualified man in the field. Good man.

Senator NELSON, Dr. Walter Richard Burack, Harvard Medical School; Dr. Melvin D. Small, Georgetown Medical School; Dr. James Haughton, first deputy administrator, Health Services Administration, New York City; Dr. Harry L. Williams, professor of pharmacology, Emory University; Dr. D. F. McGee, chairman, Department of Pharmacology, Creighton University; Dr. Lloyd C. Miller, director of revision, United States Pharmacopeia—your organization participates in the standards for establishing the standards for the drugs in the Pharmacopeia—Dr. Solomon Garb, Department of Pharmacology, University of Missouri; Dr. J. Fitelson, drug and therapeutic information, New York; Dr. Leighton Cluff, chairman, Department of Medicine, University of Florida; Dr. Margaret McCarron, Los Angeles County Hospital; Harold W. Burrows, president, Parke-Davis Co., Detroit; W. H. Conzen, president, Schering Corp., New Jersey; Dr. Calvin Kunin, Department of Preventive Medicine, University of Virginia; Dr. Martin Cherkasky, director, Montefiore Hospital, Bronx, N.Y.; Dr. James Goddard, Commissioner of FDA; Henry DeBoest, vice president of the Eli Lilly Co.; Richard Furlough, president, E. R. Squibb & Sons; Dr. Frederick Wolff, director of research, Washington Hospital Center, professor of medicine at George Washington School of Medicine; President Silloway of CIBA; George Callahan, sales projects manager, American Telephone & Telegraph Co.; Dr. James Goddard, again, Commissioner, Food and Drug Administration; Dr. Edward G. Feldmann, director of the National Formulary. Aren't these distinguished people with knowledge in this field?

Mr. STETLER. Some are and some are not.

Senator NELSON. Which ones are not?

Mr. STETLER. Well, some of them are relatively unknown. I am sure they have a right to their own view, and they expressed it. But I make the point there are others who speak for greater numbers, who are